Yahoo Finance

PD-L1 X 4-1BB (CD137) Bispecific Antibodies Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of PD-L1 x 4-1BB (CD137) Bispecific Antibodies" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report ...
Yahoo Finance

Global Development Accelerates: Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Granted Fast Track Designation by FDA

Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated: "With Opamtistomig now receiving Fast Track Designation from the FDA—following Breakthrough Therapy Designation in China and Orphan ...
Mena FN

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Dosed First Patient In New Indication, Paving A New Immunotherapy Pathway For TNBC Patients

(MENAFN- GetNews) Nanjing, China - February 10, 2026 - Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the“Company,” Stock Code: 9887) today announced that the first patient has been successfully ...
Pharmabiz

Antengene announces preclinical study results on PD-L1/4-1BB bispecific antibody ATG-101

Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class ...
Nasdaq

Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at ...

BOSTON, MA / ACCESSWIRE / April 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® ...